IN THE NEWS

BOTHELL, WA – Cardiac Science Corporation, a global leader in advanced cardiac monitoring and defibrillation products, announced today the launch of the Quinton Q-Tel RMS^® 3.0. This significant advance to the trusted Quinton line of cardiac rehabilitation systems offers several connectivity upgrades and workflow advancements to enable the best possible treatment decisions in cardiac rehabilitation.

Some of the Q-Tel 3.0 key advancements include:

• Bi-directional connectivity to a hospital’s EMR and HIS system
• Improved tracking of HIPAA compliance requirements through user activity logs.
• Session Recovery advancements to prevent the loss of patient data due to power interruption or application error.
• Q-Tel Pocket Assistant for wireless session management, enabling users to customize data entry parameters and formats for resting, exercise and recovery data by program type.

“Quinton Q-Tel connects the clinician to the enterprise EMR, the patient, the medical staff and the latest technology,” said René Mitchell, director of diagnostic marketing at Cardiac Science.  “In addition to offering nurses and exercise physiologists   the reliable, high-performance rehab technology they have come to expect from the Q-Tel system, Q-Tel 3.0 improves workflow efficiency with enhanced connectivity, allowing the rehab department to connect to the hospital’s HIS and EMR system. These enhancements were in direct response to our customers’ feedback on what would enable them to make the best possible treatment decisions, and manage their workflow most effectively.”

Frost & Sullivan, the global growth consulting company, has awarded Cardiac Science its 2007 award for Global Excellence in ECG Monitoring, recognizing Cardiac Science’s superior leadership and vision to provide superior healthcare solutions in the cardiac monitoring market.

About Cardiac Science

Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick^®, HeartCentrix^®, Powerheart^®, and Quinton^® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT

For information, contact (media) Anastasia Mironova amironova@cardiacscience.com+1.425.402.2092 | (investors) ir@optoindia.com | +91.80.2852.8088 LOGO: http://www.cardiacscience.com/images/main_logo.gif